FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1978993973> ?p ?o ?g. }

• W1978993973 endingPage "379" @default.
• W1978993973 startingPage "373" @default.
• W1978993973 abstract "Visfatin, ghrelin, and apelin are the most recently identified adipocytokines; but their response to insulin-sensitizing agents is poorly clarified. We aimed to assess the differential effects of either rosiglitazone or metformin monotherapy on the aforementioned adipocytokines in patients with type 2 diabetes mellitus (T2DM). One hundred T2DM patients (30 men, 70 women), with poor glycemic control (glycosylated hemoglobin >6.5%) while taking 850 mg of metformin daily, were enrolled. All participants were randomized to receive either adjunctive therapy with rosiglitazone (8 mg/d, n = 50) or the maximum dose (2550 mg/d) of metformin (MET group, n = 50). Anthropometric parameters, glycemic and lipid profile, high-sensitivity CRP (hs-CRP), insulin resistance (homeostasis model assessment of insulin resistance index [HOMA-IR]), visfatin, ghrelin, and apelin were assessed at baseline and after 14 weeks of therapy. Both rosiglitazone and metformin led to similar, significant improvement in glycemic profile and apelin levels, whereas lipid parameters, fat mass, and visfatin remained almost unaffected (P > .05). Insulin resistance was significantly attenuated in both groups, but to a lesser degree in the MET group (P = .045). Rosiglitazone-treated patients experienced a significant decrease in hs-CRP and systolic blood pressure compared with baseline values and those of the MET group (P < .05). Besides, rosiglitazone treatment considerably increased plasma ghrelin (3.74 ± 1.52 ng/mL) in comparison with either baseline (P = .034) or metformin monotherapy values (−2.23 ± 1.87 ng/mL, P = .008). On the other hand, the MET group, rather than the rosiglitazone group, had decreased body mass index (−0.79 ± 0.47 vs 0.56 kg/m2, P = .009). The aforementioned changes in apelin and ghrelin were independently associated with HOMA-IR changes. Both rosiglitazone and metformin favorably changed glycemic indexes and apelin levels. The addition of rosiglitazone seemed to confer greater benefits in ghrelin, hs-CRP, systolic blood pressure, and HOMA-IR regulation than metformin monotherapy. Although these results reflect improvement in cardiovascular risk profile, the overall clinical importance of insulin sensitizers must be further assessed." @default.
• W1978993973 created "2016-06-24" @default.
• W1978993973 creator A5018668950 @default.
• W1978993973 creator A5019793729 @default.
• W1978993973 creator A5023562432 @default.
• W1978993973 creator A5030182801 @default.
• W1978993973 creator A5032842969 @default.
• W1978993973 creator A5066707911 @default.
• W1978993973 creator A5086293816 @default.
• W1978993973 creator A5087628037 @default.
• W1978993973 date "2010-03-01" @default.
• W1978993973 modified "2023-10-17" @default.
• W1978993973 title "Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus" @default.
• W1978993973 cites W1966508121 @default.
• W1978993973 cites W1967565112 @default.
• W1978993973 cites W1968994034 @default.
• W1978993973 cites W1974168061 @default.
• W1978993973 cites W1982022154 @default.
• W1978993973 cites W1985643446 @default.
• W1978993973 cites W1987941106 @default.
• W1978993973 cites W1989200821 @default.
• W1978993973 cites W1998227193 @default.
• W1978993973 cites W2002811789 @default.
• W1978993973 cites W2007453649 @default.
• W1978993973 cites W2016521230 @default.
• W1978993973 cites W2017316387 @default.
• W1978993973 cites W2018677912 @default.
• W1978993973 cites W2031431332 @default.
• W1978993973 cites W2032151034 @default.
• W1978993973 cites W2035838062 @default.
• W1978993973 cites W2051795474 @default.
• W1978993973 cites W2063867076 @default.
• W1978993973 cites W2068771126 @default.
• W1978993973 cites W2073055216 @default.
• W1978993973 cites W2077861475 @default.
• W1978993973 cites W2086995303 @default.
• W1978993973 cites W2094662494 @default.
• W1978993973 cites W2108785796 @default.
• W1978993973 cites W2112133879 @default.
• W1978993973 cites W2113359468 @default.
• W1978993973 cites W2114248553 @default.
• W1978993973 cites W2119580431 @default.
• W1978993973 cites W2123706364 @default.
• W1978993973 cites W2124483055 @default.
• W1978993973 cites W2126447922 @default.
• W1978993973 cites W2126571748 @default.
• W1978993973 cites W2127125241 @default.
• W1978993973 cites W2127727717 @default.
• W1978993973 cites W2129563195 @default.
• W1978993973 cites W2135110328 @default.
• W1978993973 cites W2138842915 @default.
• W1978993973 cites W2145921233 @default.
• W1978993973 cites W2152256079 @default.
• W1978993973 cites W2162702313 @default.
• W1978993973 cites W4230492249 @default.
• W1978993973 doi "https://doi.org/10.1016/j.metabol.2009.08.005" @default.
• W1978993973 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19815243" @default.
• W1978993973 hasPublicationYear "2010" @default.
• W1978993973 type Work @default.
• W1978993973 sameAs 1978993973 @default.
• W1978993973 citedByCount "65" @default.
• W1978993973 countsByYear W19789939732012 @default.
• W1978993973 countsByYear W19789939732013 @default.
• W1978993973 countsByYear W19789939732014 @default.
• W1978993973 countsByYear W19789939732015 @default.
• W1978993973 countsByYear W19789939732016 @default.
• W1978993973 countsByYear W19789939732018 @default.
• W1978993973 countsByYear W19789939732019 @default.
• W1978993973 countsByYear W19789939732020 @default.
• W1978993973 countsByYear W19789939732021 @default.
• W1978993973 countsByYear W19789939732023 @default.
• W1978993973 crossrefType "journal-article" @default.
• W1978993973 hasAuthorship W1978993973A5018668950 @default.
• W1978993973 hasAuthorship W1978993973A5019793729 @default.
• W1978993973 hasAuthorship W1978993973A5023562432 @default.
• W1978993973 hasAuthorship W1978993973A5030182801 @default.
• W1978993973 hasAuthorship W1978993973A5032842969 @default.
• W1978993973 hasAuthorship W1978993973A5066707911 @default.
• W1978993973 hasAuthorship W1978993973A5086293816 @default.
• W1978993973 hasAuthorship W1978993973A5087628037 @default.
• W1978993973 hasConcept C126322002 @default.
• W1978993973 hasConcept C134018914 @default.
• W1978993973 hasConcept C170493617 @default.
• W1978993973 hasConcept C194832188 @default.
• W1978993973 hasConcept C2776923340 @default.
• W1978993973 hasConcept C2777180221 @default.
• W1978993973 hasConcept C2777391703 @default.
• W1978993973 hasConcept C2778270857 @default.
• W1978993973 hasConcept C2778384471 @default.
• W1978993973 hasConcept C2779306644 @default.
• W1978993973 hasConcept C2779357093 @default.
• W1978993973 hasConcept C2779546753 @default.
• W1978993973 hasConcept C2780152017 @default.
• W1978993973 hasConcept C2780221984 @default.
• W1978993973 hasConcept C2780323712 @default.
• W1978993973 hasConcept C2780473172 @default.
• W1978993973 hasConcept C2780613262 @default.
• W1978993973 hasConcept C2910068830 @default.

• next